

1 **Environment-Wide Association Study of Cognitive Function in U.S. Older**
2 **Adults using the NHANES Data**

3

4 HyunA Jang,¹ Jiyun Lee,^{1,*} Vy Kim Nguyen,² and Hyeong-Moo Shin¹

5

6 ¹Department of Environmental Science, Baylor University, Waco, TX, USA

7 ²Department of Biomedical Informatics, Medical School, Harvard University, Boston, MA, USA

8

9 *** Address correspondence to**

10 Jiyun Lee, Ph.D.

11 Department of Environmental Science, Baylor University, Waco, TX, USA

12 E-mail: Jiyun_Lee@baylor.edu

13 **Abstract**

14 Neurodegenerative diseases pose increasing challenges to global aging populations.
15 Cognitive decline in older adults is an initial indicator of neurodegenerative diseases, yet
16 comprehensive research on environmental chemical exposures related to cognitive decline is
17 limited. This study uses Environment-Wide Association Study (EWAS) framework to investigate
18 associations of environmental chemicals with cognitive function in individuals aged ≥ 60 years.
19 We used the Digit Symbol Substitution Test (DSST) scores (lower scores indicate cognitive
20 decline) and chemical biomarker data of the U.S. National Health and Nutrition Examination
21 Survey (NHANES) spanning four cycles (1999-2000, 2001-2002, 2011-2012, 2013-2014). We
22 conducted multiple survey-weighted regression to identify biomarkers associated with DSST
23 scores, penalized logit regression to estimate odds ratio (OR) of cognitive decline with identified
24 biomarkers, and correlation network analyses to examine relationships among identified
25 biomarkers and cognitive decline. After correction for multiple comparisons, 27 out of 173
26 biomarkers having a $\geq 10\%$ detection rate were associated with DSST scores (q -value < 0.05).
27 Among them, increased odds of cognitive decline were associated with elevated levels of blood
28 lead (Pb) (OR = 1.12, 95% CI: 1.01, 1.42), blood 1,4-dichlorobenzene (1,4-DCB) (OR = 1.34, 95%
29 CI: 1.17, 1.54), and urinary 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) (OR = 1.34,
30 95% CI: 1.10, 1.62). Correlation network showed biomarkers that potentially impact cognitive
31 decline upon related health conditions, such as stroke. In conclusion, leveraging the EWAS
32 framework enables us to identify chemical biomarkers that were not previously discovered from
33 traditional approaches of examining a small number of chemicals at a time. While our findings
34 provide foundation for further research, longitudinal studies are warranted to elucidate causal
35 relationships.

36

37 **Keywords**

38 Chemical exposure; Cognitive function; Environment-Wide Association Study (EWAS);

39 National Health and Nutrition Examination Survey (NHANES); Older adults

40 **Introduction**

41 Increasing incidence of neurodegenerative diseases poses a prominent challenge in
42 societies experiencing global population aging.¹ In the United States (U.S.) alone, more than 6.2
43 million people were affected by neurodegenerative diseases in 2022, including Alzheimer's
44 disease.² These diseases accounted for approximately 300,000 deaths and 3 million disability-
45 adjusted life years (DALYs) during 1990-2016.³⁻⁵ The prevalence of clinical Alzheimer's disease
46 among adults aged 65 years and older is projected to increase from 7.2 million in 2025 to 13.9
47 million in 2060.⁶ In 2021, the U.S. incurred an annual cost of over \$355 billion due to
48 Alzheimer's disease and related dementias, and this societal burden is expected to increase due to
49 the increased health care cost.⁷ Consequently, there is growing attention towards the
50 identification of risk factors and treatment development for neurodegenerative diseases.⁸

51 Neurodegenerative diseases are characterized by the progressive loss of neurons, leading
52 to deterioration in both the structure and function of neural networks.⁹ This deterioration
53 ultimately leads to impaired cognitive function.^{1,10} Gradual cognitive decline in old age is
54 typically limited to subtle declines that evolve slowly over the years, attributed to normative
55 developmental processes.^{11,12} Conversely, mild or precipitous declines in cognitive function can
56 lead to pathological processes underlying Alzheimer's disease and related dementias.^{11,13} Thus,
57 early detection of changes in cognitive function, such as mild cognitive impairment, enables
58 timely diagnosis and treatment of neurodegenerative diseases, potentially delaying disease
59 progression.^{13,14}

60 The risk of cognitive decline generally increases due to a combination of genetic and
61 non-genetic factors. Age and genetic factors, including family history and susceptibility genes
62 such as the apolipoprotein E ϵ 4 allele, are the most significant contributors to cognitive

63 decline.^{15,16} Other well-known non-genetic risk factors include comorbidities (hypertension,
64 diabetes, stroke), unhealthy diet, physical inactivity, smoking, and alcohol consumption.^{17,18}
65 These risk factors could influence the susceptibility of individual's cognitive function (e.g.,
66 disease onset, timing, severity) by interacting with genetic factors.^{16,19,20} Therefore, identifying
67 and understanding modifiable risk factors of cognitive decline could be a proactive approach to
68 promoting cognitive health.^{17,21}

69 Several studies have assessed associations between exposures to environmental
70 chemicals and cognitive decline in specific populations. For example, exposures to metals,
71 typically manganese (Mn),²²⁻²⁴ cadmium (Cd),²⁴⁻²⁷ lead (Pb),²⁵⁻²⁷ barium (Ba),²⁴ cobalt (Co),²⁴
72 cesium (Cs),²⁴ and thallium (Tl)²⁴ were reported to increase the risk of low cognitive
73 performance. In addition, higher urinary 3-phenoxybenzoic acid concentrations in adults were
74 associated with cognitive dysfunction²⁸ and it was observed that butyl benzyl phthalate is a
75 potential cognitive-disrupting compound.²⁹ However, previous studies examined exposure to a
76 small number of chemicals or compounds individually in association with cognitive function. In
77 addition, they are neither systematic nor comprehensive.

78 Environmental-Wide Association Studies (EWAS), derived from Genome-Wide
79 Association Studies (GWAS), are a useful approach for systematically and comprehensively
80 evaluating associations between hundreds of environmental factors and health outcomes.³⁰ While
81 GWAS aim to identify genetic factors associated with diseases of interest, EWAS focus on
82 assessing environmental factors. Over the past decade, several EWAS studies have been
83 conducted to elucidate the relationship between environmental chemical exposures and health
84 outcomes.³¹ Frequently-studied health outcomes were type 2 diabetes,^{30,32,33} obesity,^{34,35} and
85 blood pressure.^{36,37} Other outcomes included liver enzymes,³⁸ mental and social well-being,³⁹

86 testosterone deficiency,⁴⁰ diabetic retinopathy,⁴¹ multiple sclerosis,⁴² peripheral arterial disease,⁴³
87 and cardiovascular disease.⁴⁴ However, no studies have simultaneously and comprehensively
88 examined environmental chemical exposures associated with cognitive decline in older adults.

89 This study aims to identify environmental chemical biomarkers associated with cognitive
90 decline in U.S. older adults by using the EWAS approach and the National Health and Nutrition
91 Examination Survey (NHANES) data. First, to screen chemicals or their biomarkers, we
92 examined a single association for each biomarker and identified those that were statistically
93 significant after controlling for multiple comparisons. Second, we evaluated the effects of
94 multiple exposures to those identified biomarkers on cognitive decline. Finally, we extracted a
95 correlation network structure to explore potential pathways between chemical exposures and
96 cognitive decline and further assessed the potential mediating effect of other modifiable factors.


97

98 **2. Methods**

99 ***2.1. Study population***

100 NHANES is conducted every two years in the U.S. by the Centers for Disease Control
101 and Prevention (CDC) and the National Centers for Health Statistics (NCHS). This is a cross-
102 sectional survey designed to assess the health and nutritional status of both adults and children.
103 To obtain a representative sample of the U.S. population, complex, multi-stage, and probability
104 sampling techniques are used. NHANES data are publicly available (at
105 <https://www.cdc.gov/nchs/nhanes>) and include individual questionnaires, physical examinations,
106 and laboratory tests. More details on the design and methods of the NHANES data are available
107 elsewhere.⁴⁵

108 Our study combined data from four cross-sectional surveys conducted in 1999-2000,
109 2000-2001, 2011-2012, and 2013-2014, each of which included assessments of cognitive
110 function. Targeting older adults (age ≥ 60 years), our analysis consisted of 4,970 individuals after
111 excluding those with missing cognitive function data (n = 34,774) and those with abnormal
112 urinary creatinine levels (n = 1,191) (Figure 1). The NCHS Ethics Review Board has approved
113 this survey (Protocol #98-12 for NHANES 1999-2002 data, Protocol #2011-17 for NHANES
114 2011-2014 data), and all participants completed informed consent forms.



115

116 **Figure 1.** The process of data integration, non-targeted screening, and extended analysis. Data
 117 from four cycles of the National Health and Nutrition Examination Survey (NHANES) were
 118 used in this study. Final study subjects and environmental factors included in this study were
 119 selected based on specified inclusion and exclusion criteria.

120

121 2.2. Cognitive function assessment

122 In NHANES, the Digit Symbol Substitution Test (DSST), a subscale of the Wechsler
 123 Adult Intelligence Scale, was utilized to evaluate primary cognitive processing speed, attention,
 124 and working memory.⁴⁶ Its application aids in determining the presence of cognitive dysfunction
 125 across various stages, including preclinical, prodromal, and dementia phases.^{47,48} Administered in

126 a paper-and-pencil format, this cognitive test requires individuals to match symbols to
127 corresponding numbers based on a provided key.⁴⁹ The score is the total number of correct
128 matches within 90 to 120 seconds, with lower scores indicating diminished cognitive function.⁴⁹
129 Since 1999, NHANES has administered this test in participants aged 60 years and older. This test
130 occurs during face-to-face interviews at the Mobile Examination Center by trained interviewers.
131 Participants have the option to select from English, Spanish, Korean, Vietnamese, or Chinese. In
132 this study, we used DSST z-scores when screening chemical biomarkers related to cognitive
133 function and DSST raw scores below the 25th percentile when defining as cognitive decline, as
134 used by NCHS reports⁵⁰ and other previous studies.^{51,52}

135

136 ***2.3. Measurement of environmental chemical biomarkers***

137 In NHANES, environmental chemical biomarker data were collected from the blood and
138 urine samples of randomly selected participants within specific age groups in a one-third sample.
139 Because detailed biological sample collection methods from NHANES participants vary by
140 cycle,⁵³⁻⁵⁶ we used a harmonized and unified version of the NHANES chemical biomonitoring
141 data.⁵⁷ A total of 381 environmental chemical biomarkers were examined across the four cycles.
142 These chemicals could be grouped as follows: acrylamide (n = 2), aldehydes (n = 13), aromatic
143 amines (n = 16), dietary components (n = 6), dioxins (n = 14), furans (n = 20), metals (n = 29),
144 per- and polyfluoroalkyl substances (PFAS) (n = 11), personal care & consumer product
145 compounds (PCCPCs) (n = 12), pesticides (n = 55), phosphate flame retardants (PFR) (n = 9),
146 phthalates & plasticizers (n = 14), polyaromatic hydrocarbons (PAHs) (n = 12), polychlorinated
147 biphenyls (PCBs) (n = 70), smoking-related compounds (SRCs) (n = 15), and volatile organic
148 compounds (VOCs) (n = 83). Detailed information, including the number of observations,

149 detection rate, and lower limit of detection (LLOD) value, is given in Table S1 of Supplementary
150 Information. In NHANES, all chemical biomarker concentrations below the LLOD were
151 replaced with the $LLOD/\sqrt{2}$. The distribution of each biomarker concentration is provided in
152 Table S2. The NHANES website offers detailed laboratory measurement methods and quality
153 control procedures (<https://wwwn.cdc.gov/nchs/nhanes/>).

154

155 **2.4. Covariates**

156 We selected 11 covariates which are potential confounding or risk factors for cognitive
157 decline identified in previous studies: sex (men and women), age group (60-64, 65-69, 70-74, 75-
158 79, and ≥ 80 years), race/ethnicity (non-Hispanic white, non-Hispanic black, Mexican
159 American/Hispanic, and others), marital status (married or living with partner, never married,
160 divorced or separated, and widowed), education level (<high school, high school, and >high
161 school), body mass index (<25, 25-<30, 30-<40, and ≥ 40 kg/m²),⁵⁸ cotinine level as a proxy of
162 smoking status (<3 and ≥ 3 ng/mL),⁵⁹ alcohol consumption (non-drinker and drinker), health
163 conditions (hypertension, diabetes, and stroke). Alcohol consumption and health conditions were
164 ascertained by self-reported questionnaires (variable name in NHANES): “Had at least 12
165 alcohol drinks/lifetime? (ALQ110)”, “Ever told you had high blood pressure? (BPQ020)”, “Ever
166 told you have diabetes? (DIQ010)” and “Ever told you had a stroke? (MCQ160f)”.

167

168 **2.5. Statistical analysis**

169 Descriptive statistics of participant characteristics were summarized using mean \pm
170 standard deviation (SD), number of cases (n), and percentage (%). The differences in DSST
171 scores among each covariate were compared using t-tests and ANOVA. A cognitive decline

172 group (i.e., participants with the lowest 25th percentile DSST scores) and a normal group (i.e.,
173 the rest as a reference) were compared using the chi-squared test. All analyses were performed
174 using R version 4.3.1 (R Core Team, <https://www.R-project.org/>). The critical level of
175 significance was set at $\alpha = 0.05$.

176

177 *2.5.1. Screening environmental chemical biomarkers related to cognitive function scores*

178 To screen hundreds of chemical biomarkers that are associated with lower DSST z-scores,
179 we performed an EWAS non-targeted screening approach and identified biomarkers potentially
180 affecting cognitive function. During this step, we used complete-cases data without missing
181 values and considered chemicals with a detection rate of $\geq 10\%$. All concentrations were log₁₀-
182 transformed to control a right-skewed distribution and z-standardized. We explored the
183 association between each biomarker and DSST z-scores using multiple survey-weighted
184 regression adjusted for all covariates. To account for the complex survey design, we calculated
185 sample weights following the NHANES guidelines.⁶⁰ P-values were corrected using the false
186 discovery rate (FDR, *q*-value) (Figure 1).

187

188 *2.5.2. Associations between exposure to identified biomarkers and cognitive decline*

189 After identifying chemical biomarkers associated with DSST z-scores from the first step
190 (*q*-value <0.05), we divided our participants into two groups (a normal group vs. a cognitive
191 decline group) and examined associations of chemical exposures with cognitive decline by only
192 including the identified chemical biomarkers with a detection rate of $\geq 50\%$ and variance
193 inflation factor (VIF) <10 in the model. We employed a multivariate imputation by chained
194 equations (MICE) technique assuming ‘missing-at-random (MAR)’ to create 10 imputed

195 datasets.⁶¹ To reduce imputation bias due to temporal trends in chemical biomarker, we generated
196 imputed data separately for each of the 1999-2002 and 2011-2014 cycles and estimated the odds
197 ratio (OR) and 95% confidence intervals (CI) of cognitive decline associated with biomarker
198 levels using penalized logit regression with the Akaike Information Criterion (AIC) adjusted for
199 all covariates.

200

201 *2.5.3. Interactive impact of chemical biomarkers and selected covariates on cognitive decline*

202 To uncover the interactive impact of identified chemical biomarkers and the selected
203 covariates on cognitive decline, we first combined imputed data from both the 1999-2002 and
204 2011-2014 cycles, focusing solely on chemical biomarkers consistently measured across all
205 cycles. Next, we utilized Gaussian Graphical Models (GGMs) with the desparsified Lasso to
206 derive a partial correlation network structure encompassing the identified chemical biomarkers,
207 cognitive decline, and all covariates. Significant *p*-values were adjusted using the Holm–
208 Bonferroni method. We selected non-chemical factors exhibiting statistically significant
209 correlation coefficients with cognitive decline. Finally, we conducted stratified analyses on each
210 category of the non-chemical factors to assess their potential as mediators using logistic
211 regression adjusted for other covariates.

212

213 **3. Results**

214 *3.1. Characteristics of study participants*

215 Overall, 4,970 participants were included in this study, with 1,305 participants classified
216 as the cognitive decline group. Significant differences in DSST z-scores were observed across all
217 covariates (Table 1). Men had lower DSST z-scores than women, and Mexican

218 Americans/Hispanics or widowed individuals had the lowest z-scores. DSST z-scores tended to
219 decrease with increasing age or lower education levels. Smokers scored lower than non-smokers,
220 whereas participants who consumed alcohol scored higher than those who never drank alcohol.
221 No trend was observed with changes in BMI.

222 **Table 1.** Characteristics of the National Health and Nutrition Examination Survey (NHANES) study
 223 participants (1999-2000, 2001-2002, 2011-2012, and 2013-2014) included in this study (total = 4,970).

	Digit Symbol Substitution Test (DSST) scores			Cognitive decline ^a		<i>p</i> -value ^c
	n (%)	Mean ± SD	<i>p</i> -value ^b	Cognitive normality	Cognitive decline	
				(n = 3,665)	(n = 1,305)	
			n (%)	n (%)		
Sex			<0.001			<0.001
Men	2,545 (51.2)	41.6 ± 17.2		1,805 (49.2)	740 (56.7)	
Women	2,425 (48.8)	45.6 ± 18.7		1,860 (50.8)	565 (43.3)	
Age (years)			<0.001			<0.001
60-64	1,441 (29.0)	49.5 ± 18.7		1,177 (32.1)	264 (20.2)	
65-69	1,070 (21.5)	45.0 ± 18.0		814 (22.2)	256 (19.6)	
70-74	946 (19.0)	42.9 ± 17.1		705 (19.2)	241 (18.5)	
75-79	605 (12.2)	38.9 ± 16.3		409 (11.2)	196 (15.0)	
Over 80	908 (18.3)	36.2 ± 15.4		560 (15.3)	348 (26.7)	
Body mass index (BMI, kg/m²)			<0.001			<0.001
Underweight or normal (BMI <25)	1,293 (26.0)	43.5 ± 18.4		946 (25.8)	347 (26.6)	
Overweight (25 ≤ BMI <30)	1,847 (37.2)	43.6 ± 17.9		1,377 (37.6)	470 (36.0)	
Obesity (30 ≤ BMI <40)	1,456 (29.3)	44.3 ± 17.9		1,093 (29.8)	363 (27.8)	
Severe obesity (BMI ≥40)	233 (4.7)	44.7 ± 17.4		179 (4.9)	54 (4.1)	
Unknown	141 (2.8)	33.5 ± 16.1		70 (1.9)	71 (5.4)	
Race/ethnicity			<0.001			<0.001
Non-Hispanic white	2,626 (52.8)	48.5 ± 16.8		2,212 (60.4)	414 (31.7)	
Non-Hispanic black	986 (19.8)	37.3 ± 16.8		599 (16.3)	387 (29.7)	
Mexican American/Hispanic	1,062 (21.4)	35.7 ± 17.7		609 (16.6)	453 (34.7)	
Others	296 (6.0)	48.8 ± 17.8		245 (6.7)	51 (3.9)	
Marital status			<0.001			<0.001
Married or living with partner	2,951 (59.4)	45.8 ± 17.9		2,294 (62.6)	657 (50.3)	
Never married	203 (4.1)	43.2 ± 18.7		142 (3.9)	61 (4.7)	
Divorced or separated	681 (13.7)	43.1 ± 18.1		487 (13.3)	194 (14.9)	
Widowed	1,026 (20.6)	38.3 ± 17.1		664 (18.1)	362 (27.7)	
Unknown	109 (2.2)	37.0 ± 18.2		78 (2.1)	31 (2.4)	
Education level			<0.001			<0.001
< High school	1,607 (32.3)	30.9 ± 15.3		766 (20.9)	841 (64.4)	
High school	1,173 (23.6)	44.8 ± 15.9		921 (25.1)	252 (19.3)	
> High school	2,182 (43.9)	52.3 ± 15.4		1,975 (53.9)	207 (15.9)	
Unknown	8 (0.2)	29.4 ± 18.6		3 (0.1)	5 (0.4)	
Cotinine level as a proxy of smoking status (ng/mL)			<0.001			<0.001
Low (<3)	3,912 (78.7)	44.5 ± 18.1		2,964 (80.9)	948 (72.6)	
High (≥3)	789 (15.9)	40.3 ± 17.5		526 (14.4)	263 (20.2)	
Unknown	269 (5.4)	38.9 ± 17.6		175 (4.8)	94 (7.2)	
Alcohol consumption			<0.001			<0.001
Non-drinker	797 (16.0)	39.5 ± 17.7		526 (14.4)	271 (20.8)	
Drinker	877 (17.6)	42.3 ± 17.8		645 (17.6)	232 (17.8)	
Unknown	3,296 (66.3)	44.9 ± 18.0		2,494 (68.0)	802 (61.5)	
Health conditions			<0.001			0.009
Ever told you had high blood pressure						

No	2,129 (42.8)	45.2 ± 18.4		1,637 (44.7)	492 (37.7)	
Yes	2,833 (57.0)	42.3 ± 17.6		2,022 (55.2)	811 (62.1)	
Unknown	8 (0.2)	43.6 ± 25.2		6 (0.2)	2 (0.2)	
Ever told you have diabetes			<0.001			<0.001
No	3,779 (76.0)	44.7 ± 18.3		2,875 (78.4)	904 (69.3)	
Yes	1,007 (20.3)	38.9 ± 17.0		654 (17.8)	353 (27.0)	
Unknown	184 (3.7)	44.9 ± 15.6		136 (3.7)	48 (3.7)	
Ever told you had a stroke			<0.001			<0.001
No	4,630 (93.2)	44.2 ± 18.0		3,476 (94.8)	1,154 (88.4)	
Yes	330 (6.6)	34.2 ± 16.4		181(4.9)	149 (11.4)	
Unknown	10 (0.2)	44.6 ± 13.9		8 (0.2)	2 (0.2)	


224 ^a Cognitive decline was defined as less than the 25th percentile of Digit Symbol Substitution Test
 225 (DSST) raw scores.

226 ^b *p*-value was estimated using t-test or ANOVA.

227 ^c *p*-value was estimated using the Chi-square test.

228 **3.2. Identified chemical biomarkers related to cognitive function test scores**

229 Out of 381 environmental chemical biomarkers examined across all four NHANES
230 cycles, we only evaluated 173 biomarkers with a detection rate of $\geq 10\%$ (Figure 1). Among the
231 173 chemicals, 27 were associated with DSST z-scores (q -value < 0.05). These included metals
232 ($n = 11$), PAHs ($n = 3$), PCBs ($n = 3$), pesticides ($n = 3$), phthalates ($n = 2$), and one each of
233 PCCPCs, phytoestrogens, VOCs, flame retardants, and SRCs (Figure 2). PAHs, PCBs, phthalates,
234 SRCs, and VOCs each decreased DSST z-scores, whereas flame retardants, PCCPCs, and
235 phytoestrogens increased the scores. Metals and pesticides had varying effects depending on the
236 biomarker (Table S3). For example, per 1 standard deviation increase in log₁₀-transformed blood
237 lead (Pb) level, DSST z-scores decreased by 0.09.



238
 239 **Figure 2.** Manhattan plot of environmental factors (chemical biomarkers) associated with the Digit Symbol Substitution Test (DSST)
 240 z-scores. Significant chemical biomarkers were dotted above the grey dashed line (q -value < 0.05), and the arrows indicated the
 241 direction of their effects on DSST z-scores. Abbreviation: B, blood; DDT, dichlorodiphenyltrichloroethane; NNAL, 4-
 242 (methylnitrosamino)-1-(3-pyridyl)-1-butanol; PCB, polychlorinated biphenyl; U, urine.

243 **3.3. Associations between exposure to identified chemicals and cognitive decline**

244 After screening chemical biomarkers that were associated with DSST z-scores, we
245 examined associations between the identified biomarkers and cognitive decline by restricting
246 analyses to those with a detection rate of $\geq 50\%$ and separating the entire data to 1999-2002 and
247 2011-2014 cycles. When using the data collected during the 1999-2002 cycle, we could evaluate
248 only 8 out of the 27 identified biomarkers, because the other 19 biomarkers were not measured
249 during this cycle or had detection rates below 50%. From this cycle, blood Pb increased the odds
250 of having cognitive decline (OR = 1.12, 95% CI: 1.01, 1.42), whereas blood cadmium (Cd)
251 decreased the odds (OR = 0.78, 95% CI: 0.64, 0.96) (Table 2). From the 2011-2014 cycle data,
252 we evaluated 18 biomarkers after excluding those that were not measured during this cycle or
253 highly correlated chemicals with a VIF > 10 . From this cycle, blood 1,4-DCB and urinary 4-
254 (methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) increased the odds of having cognitive
255 decline (OR = 1.34, 95% CI: 1.17, 1.54 and OR = 1.34, 95% CI: 1.10, 1.62, respectively).

256 **Table 2.** Associations between 27 identified environmental chemical biomarkers and cognitive
 257 decline by two combined cycles (NHANES 1999-2002 and 2011-2014) (total = 4,970).

	NHANES 1999-2002 (n = 1,641, Case ^a = 693)	NHANES 2011-2014 (n = 2,043, Case ^a = 593)
	OR (95% CI)	OR (95% CI)
Metals		
In blood		
Cadmium	0.78 (0.64, 0.96)^a	0.89 (0.57, 1.39)
Lead	1.20 (1.01, 1.42)^a	0.997 (0.23, 4.27)
Methylmercury	b	0.83 (0.51, 1.35)
Total mercury	b	c
In urine		
Cesium	0.74 (0.07, 7.64)	0.39 (0.02, 6.22)
Thallium	1.04 (0.06, 18.16)	2.08 (0.13, 33.17)
Cadmium	b	1.34 (0.67, 2.67)
Dimethylarsonic acid	b	1.49 (0.40, 5.51)
Mercury	b	1.63 (0.47, 5.63)
Arsenobetaine	b	0.79 (0.26, 2.35)
Total arsenic	b	c
Phthalates in urine		
Mono-ethyl phthalate	1.14 (0.25, 5.28)	1.43 (0.31, 6.53)
Mono-benzyl phthalate	1.87 (0.77, 4.56)	1.27 (0.36, 4.46)
PAHs in urine		
2-naphthol	b	1.27 (0.06, 27.98)
2-fluorene	b	c
3-fluorene	b	0.79 (0.23, 2.71)
PCBs in urine		
PCB 167	e	b
PCB 177	e	b
PCB 178	e	b
Pesticides in blood		
p,p'-DDT	2.23 (0.68, 7.36)	b
3-phenoxybenzoic acid	b	0.88 (0.04, 17.86)
Mirex	e	b
Others		
Blood 1,4-Dichlorobenzene	b	1.34 (1.17, 1.54)^a
Urinary Benzophenone-3	b	0.52 (0.18, 1.52)
Urinary Diphenyl phosphate	b	0.43 (0.02, 9.25)
Urinary Enterodiol	1.23 (0.31, 4.92)	b
Urinary NNAL	b	1.34 (1.10, 1.62)^a

258 Note: All biomarker concentrations were log₁₀-transformed and scaled. The OR and 95% CI were
 259 estimated using the penalized logistic regression model with the Akaike information criterion adjusted for
 260 sex, age group, body mass index, race/ethnicity, marital status, education level, smoking status based on
 261 the cotinine level, alcohol consumption, and health conditions (diabetes, hypertension, and stroke).

262 Abbreviation: CI, confidence interval; DDT, dichlorodiphenyltrichloroethane; NNAL, 4-
 263 (methylnitrosamino)-1-(3-pyridyl)-1-butanol; OR, odds ratio; PAH, polycyclic aromatic hydrocarbon;
 264 PCB, polychlorinated biphenyl.

265 ^a Defined as less than or equal to the 25th percentile DSST scores.

266 ^b Not measured in this cycle.

267 ^c Excluded due to multi-collinearity.


268 ^d p -value <0.05.

269 ^e Detection rate <50%.


270

271 ***3.4. Interactive impact of chemical exposures and health conditions on cognitive decline***

272 Based on the partial correlation network structure newly created in the current study,
273 cognitive decline was directly associated with non-chemical factors, including smoking, obesity,
274 alcohol consumption, and health conditions (stroke, diabetes, and hypertension) (Figure 3).
275 Environmental chemical exposures seemed to have indirect relationships with cognitive decline,
276 with health conditions serving as potential mediators. For instance, blood Cd was positively
277 correlated with stroke which was also positively correlated with cognitive decline. Thus, we
278 conducted stratified analyses by the status of stroke, diabetes, hypertension, and obesity to
279 examine the potential interactive impact of health conditions. Overall, we observed no significant
280 associations from these analyses (Figure 4). However, the odds of having cognitive decline for
281 stroke cases tended to be higher than for non-cases with increased levels of blood Cd, blood Pb,
282 urinary thallium (Tl), urinary mono-ethyl phthalate (MEP), and urinary mono-benzyl phthalate
283 (MBzP). Similarly, the odds for diabetes cases tended to be higher than for non-cases with
284 increased levels of blood Cd, urinary Tl, urinary cesium (Cs), urinary MEP, and urinary MBzP.
285 The odds for hypertension cases tended to be higher than for non-cases with increased levels of
286 urinary Tl. The odds for obesity cases tended to be higher than for non-cases with increased
287 levels of urinary Tl, urinary MEP, and urinary MBzP.



288
 289 **Figure 3.** Partial correlation () network plot depicting the magnitude and direction of
 290 correlation coefficients among identified chemical biomarkers, cognitive decline, and selected
 291 covariates. Only chemical biomarkers or covariates with significant correlation coefficients with
 292 cognitive decline (adjusted p -value < 0.05) are shown. Green lines indicate relatively strong
 293 correlation coefficients ($|\rho| \geq 0.5$). Red numbers indicate positive correlations and blue numbers
 294 indicate negative correlations.



295
 296 **Figure 4.** Odds ratio (OR) and 95% confidence interval (CI) of cognitive decline associated with six chemical biomarkers
 297 identified from correlation network structure stratified by four health conditions (total = 4,970). All chemical biomarker
 298 concentrations were log 10-transformed and scaled.

299 4. Discussion

300 To the best of our knowledge, this study represents comprehensive and systematic
301 investigation into the association between environmental chemical exposures and cognitive
302 decline. By using the EWAS approach and the NHANES data, we screened 173 environmental
303 chemical biomarkers and identified those potentially related to cognitive decline. Additionally,
304 we estimated the odds of having cognitive decline from the identified biomarkers and
305 investigated previously undiscovered pathways linking chemical biomarkers to cognitive decline
306 by extracting a correlation network structure. This allowed us to understand that cognitive
307 decline can be worsened with increased chemical exposures among those with known risk
308 factors of cognitive decline.

309 Among 173 chemical biomarkers investigated in this study, we observed that 27
310 biomarkers were associated with DSST z-scores. Most of them were metals, PAHs, PCBs,
311 pesticides, and phthalates which are known to have neurotoxicity.⁶²⁻⁶⁶ Because these are
312 characterized by persistence and bioaccumulation,⁶⁷⁻⁷⁰ older adults might have been chronically
313 exposed throughout their lives.

314 When including all environmental chemical biomarkers identified from non-targeted
315 screening, we found that blood Pb, urinary NNAL, and urinary 1,4-DCB increased the odds of
316 cognitive decline. Previous studies have shown consistent results for the association between Pb
317 exposure and cognitive function. For instance, each 1 µg/L increase in Pb concentration was
318 associated with a 1.08-point decrease in DSST scores among U.S. older adults.²⁶ For every 1
319 µg/dL increase in Pb levels, the odds of low cognitive performance in older adults in the U.S. by
320 10%.²⁵ In addition, Pb, a ubiquitous environmental contaminant,⁷¹ is exposed primarily through
321 food, water, tobacco smoke, air, dust, and soil.⁷² When Pb enters our human body, over 90% is

322 accumulated in bones.⁷³ Thus, older adults have high levels of Pb in their bodies due to their long
323 lifespan.^{73,74} Pb can affect cognitive decline by disrupting neurotransmission⁷⁵ and promoting
324 oxidative stress⁷⁶ through altering the fluidity or permeability of cell membranes.⁷⁷ It also has
325 indirect effects due to its associations with hypertension and other cardiovascular diseases,⁷⁸ as
326 well as its long-term storage in bones.⁷⁹ Regarding NNAL, a previous study using NHANES data
327 in older adults found that the group with the highest urinary NNAL concentration had a
328 significantly lower DSST z-score by 0.19 compared to the lowest concentration group.⁸⁰ NNAL
329 is a reliable biomarker for nitrosamine ketone (NNK) exposure.⁸¹ NNK is present in the leaves of
330 *Nicotiana tabacum* grown in the U.S.⁸² and can be exposed directly or indirectly through
331 smoking,⁸³ a well-known risk factor of cognitive decline. This compound is known to increase
332 neurotoxicity by altering responses to centrally acting drugs, increasing susceptibility to
333 neurotoxins, and enhancing metabolism.⁸¹ Lastly, 1,4-DCB (or paradichlorobenzene) can be
334 easily encountered in our daily lives because it is an active ingredient in mothballs, deodorizers,
335 and fumigants.^{84,85} However, there have been no epidemiological studies on the relationship
336 between 1,4-DCB and cognitive function. Several *in vivo* studies have suggested its neurotoxic
337 mechanism. This compound has central nervous system toxicity, causing oxidative damage and
338 trace element alterations in various tissues, as well as oxidative DNA damage, leading to
339 reported cognitive decline.^{84,86,87}

340 From our correlation network analysis showing several pathways between chemical
341 biomarkers and cognitive decline, we observed that stroke had relatively strong correlation
342 coefficients with both blood Cd and cognitive decline. This finding highlights the need of this
343 network analysis because blood Cd had protective effects against cognitive decline when
344 considering other identified environmental chemicals in the regression. Previous studies have

345 shown that exposure to Cd can impair cognitive performance both in isolated exposure scenarios
346 and in combination with other environmental chemicals identified through EWAS screening.²⁴⁻²⁷
347 It is also well known that Cd causes vascular damage and promotes atherosclerosis⁸⁸ by
348 generating reactive oxygen species, disrupting sulfhydryl homeostasis, and downregulating nitric
349 oxide.⁸⁹ Stroke affects cognitive domains such as attention, memory, and language. People who
350 had stroke commonly experience cognitive impairment and memory loss, making them highly
351 likely to develop dementia within one year of stroke onset.^{90,91} While our findings suggest that
352 the effects of Cd exposure on cognitive decline may vary by individual's health conditions, the
353 specific mechanisms underlying these pathways remain unclear. Further experimental
354 investigation is warranted to elucidate the mediating effects of these health conditions on the
355 association between Cd exposure and cognitive decline.

356 Our study has several limitations. Firstly, the cross-sectional nature of the NHANES data
357 precludes establishing causation from our findings. Secondly, chemical biomarker concentration
358 data were from a spot sample of each participant, so they may not represent individual's average
359 exposure over the lifetime of our participants. Thirdly, despite adjusting for confounders
360 associated with cognitive decline based on previous studies, there may still be unmeasured
361 confounding variables influencing our effect estimates. Fourthly, there could be imputation bias
362 on the biomarker data because each NHANES cycle had a different list of chemical biomarkers
363 and only one third of samples from each cycle were used to assess chemical biomarker
364 concentrations. In addition, if the missing data mechanism of NHANES is non-random (i.e.,
365 missing not at random, MNAR), performing multiple imputation under the assumption of
366 missing at random (MAR) may produce biased estimates.⁹² Finally, the EWAS approach used in

367 this study cannot assess the effects of chemical mixtures, such as additive effects, synergism,
368 potentiation, and antagonism.

369

370 **5. Conclusions**

371 In this study, we employed an EWAS approach to explore 173 environmental chemical
372 biomarkers in association with cognitive decline among U.S. older adults. From the regression
373 including all identified biomarkers significantly associated with cognitive decline, we observed
374 positive associations between cognitive decline and Pb, 1,4-DCB, and NNAL. From the
375 correlation network structure, Cd may increase the risk of stroke which is a risk factor of
376 cognitive decline. These findings suggest that combined and prolonged exposure to these
377 chemicals may worsen cognitive impairment in aging populations. Our study underscores the
378 complex interplay between exposure to environmental chemicals and cognitive function in older
379 adults, emphasizing the need for further research to elucidate causal mechanisms and effectively
380 guide public health interventions.

381

382 **Funding**

383 This research received no specific grant from any funding agency in the public,
384 commercial, or not-for-profit sectors.

385

386 **Author contributions**

387 **HyunA Jang:** conceptualization, data curation, formal analysis, methodology, software,
388 visualization, and writing – original draft. **Jiyun Lee:** conceptualization, data curation,
389 methodology, visualization, validation, and writing – review & editing. **Vy Kim Nguyen:**

390 resources, data curation, and writing – review & editing. **Hyeong-Moo Shin:** conceptualization,
391 supervision, validation, and writing – review & editing.

392

393 **Data availability**

394 The data and R code can be shared upon request to the corresponding author.

395

396 **Conflict of interest statement**

397 The authors declare that they have no conflicts of interest.

398

399 **References**

- 400 1. Hou YJ, Dan XL, Babbar M, et al. Ageing as a risk factor for neurodegenerative disease.
401 *Nat Rev Neurol*. Oct 2019;15(10):565-581. doi:10.1038/s41582-019-0244-7
- 402 2. Alzheimer's Association. *Alzheimer's Disease Facts and Figures*. Vol. 20. 2024.
403 *Alzheimers Dement.* chrome-
404 extension://efaidnbmnnnibpcajpcglclefindmkaj/[https://www.alz.org/media/documents/alzheimers](https://www.alz.org/media/documents/alzheimers-facts-and-figures.pdf)
405 [-facts-and-figures.pdf](https://www.alz.org/media/documents/alzheimers-facts-and-figures.pdf)
- 406 3. Collaborators GBDD. Global, regional, and national burden of Alzheimer's disease and
407 other dementias, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016.
408 *Lancet Neurol*. Jan 2019;18(1):88-106. doi:10.1016/S1474-4422(18)30403-4
- 409 4. Collaborators GBDMND. Global, regional, and national burden of motor neuron diseases
410 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. *Lancet Neurol*.
411 Dec 2018;17(12):1083-1097. doi:10.1016/S1474-4422(18)30404-6
- 412 5. Collaborators GBDPsD. Global, regional, and national burden of Parkinson's disease,
413 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. *Lancet Neurol*.
414 Nov 2018;17(11):939-953. doi:10.1016/S1474-4422(18)30295-3
- 415 6. Rajan KB, Weuve J, Barnes LL, McAninch EA, Wilson RS, Evans DA. Population
416 estimate of people with clinical Alzheimer's disease and mild cognitive impairment in the United
417 States (2020-2060). *Alzheimers Dement*. Dec 2021;17(12):1966-1975. doi:10.1002/alz.12362
- 418 7. 2021 Alzheimer's disease facts and figures. *Alzheimers Dement*. Mar 2021;17(3):327-406.
419 doi:10.1002/alz.12328
- 420 8. National institute of Health. *Looking Forward: Opportunities to Accelerate Alzheimer's*
421 *and Related Dementias Research 2024*. 13, Jun. 2024.
422 https://www.nia.nih.gov/sites/default/files/2022-07/fy24_alzheimers_bypassbudget.pdf
- 423 9. Wilson DM, 3rd, Cookson MR, Van Den Bosch L, Zetterberg H, Holtzman DM,
424 Dewachter I. Hallmarks of neurodegenerative diseases. *Cell*. Feb 16 2023;186(4):693-714.
425 doi:10.1016/j.cell.2022.12.032
- 426 10. Ullah MF, Ahmad A, Bhat SH, Abu-Duhier FM, Barreto GE, Ashraf GM. Impact of sex
427 differences and gender specificity on behavioral characteristics and pathophysiology of
428 neurodegenerative disorders. *Neurosci Biobehav Rev*. Jul 2019;102:95-105.
429 doi:10.1016/j.neubiorev.2019.04.003
- 430 11. Wilson RS, Leurgans SE, Boyle PA, Schneider JA, Bennett DA. Neurodegenerative basis
431 of age-related cognitive decline. *Neurology*. Sep 21 2010;75(12):1070-8.
432 doi:10.1212/WNL.0b013e3181f39adc
- 433 12. Harada CN, Natelson Love MC, Triebel KL. Normal cognitive aging. *Clin Geriatr Med*.
434 Nov 2013;29(4):737-52. doi:10.1016/j.cger.2013.07.002
- 435 13. Kelley BJ, Petersen RC. Alzheimer's disease and mild cognitive impairment. *Neurol Clin*.
436 Aug 2007;25(3):577-609, v. doi:10.1016/j.ncl.2007.03.008

- 437 14. Andrade C, Radhakrishnan R. The prevention and treatment of cognitive decline and
438 dementia: An overview of recent research on experimental treatments. *Indian J Psychiatry*. Jan
439 2009;51(1):12-25. doi:10.4103/0019-5545.44900
- 440 15. Baumgart M, Snyder HM, Carrillo MC, Fazio S, Kim H, Johns H. Summary of the
441 evidence on modifiable risk factors for cognitive decline and dementia: A population-based
442 perspective. *Alzheimers Dement*. Jun 2015;11(6):718-26. doi:10.1016/j.jalz.2015.05.016
- 443 16. Fan J, Tao W, Li X, et al. The Contribution of Genetic Factors to Cognitive Impairment
444 and Dementia: Apolipoprotein E Gene, Gene Interactions, and Polygenic Risk. *Int J Mol Sci*.
445 Mar 7 2019;20(5)doi:10.3390/ijms20051177
- 446 17. Manuello J, Min JS, Mccarthy P, et al. The effects of genetic and modifiable risk factors
447 on brain regions vulnerable to ageing and disease. *Nature Communications*. Mar 27
448 2024;15(1)doi:ARTN 2576
449 10.1038/s41467-024-46344-2
- 450 18. Edwards Iii GA, Gamez N, Escobedo G, Jr., Calderon O, Moreno-Gonzalez I. Modifiable
451 Risk Factors for Alzheimer's Disease. *Front Aging Neurosci*. 2019;11:146.
452 doi:10.3389/fnagi.2019.00146
- 453 19. Sepulveda-Falla D, Velez JI, Acosta-Baena N, et al. Genetic modifiers of cognitive
454 decline in PSEN1 E280A Alzheimer's disease. *Alzheimers Dement*. Apr 2024;20(4):2873-2885.
455 doi:10.1002/alz.13754
- 456 20. Faouzi J, Tan M, Casse F, et al. Proxy-analysis of the genetics of cognitive decline in
457 Parkinson's disease through polygenic scores. *NPJ Parkinsons Dis*. Jan 4 2024;10(1):8.
458 doi:10.1038/s41531-023-00619-5
- 459 21. Council. WD. WDC Dementia Risk Reduction Statement. Accessed June 14, 2024.
460 chrome-extension://efaidnbmninnibpcjpcglclefindmkaj/[https://s3-eu-west-](https://s3-eu-west-1.amazonaws.com/media.dh.gov.uk/network/353/files/2015/01/WDC-supportive-statement-on-risk-reduction-FINAL-FOR-PUBLICATION-BRANDED-150128-LM.pdf)
461 [1.amazonaws.com/media.dh.gov.uk/network/353/files/2015/01/WDC-supportive-statement-on-](https://s3-eu-west-1.amazonaws.com/media.dh.gov.uk/network/353/files/2015/01/WDC-supportive-statement-on-risk-reduction-FINAL-FOR-PUBLICATION-BRANDED-150128-LM.pdf)
462 [risk-reduction-FINAL-FOR-PUBLICATION-BRANDED-150128-LM.pdf](https://s3-eu-west-1.amazonaws.com/media.dh.gov.uk/network/353/files/2015/01/WDC-supportive-statement-on-risk-reduction-FINAL-FOR-PUBLICATION-BRANDED-150128-LM.pdf)
- 463 22. Barahona AJ, Bursac Z, Veledar E, Lucchini R, Tieu K, Richardson JR. Relationship of
464 Blood and Urinary Manganese Levels with Cognitive Function in Elderly Individuals in the
465 United States by Race/Ethnicity, NHANES 2011-2014. *Toxics*. Apr 14
466 2022;10(4)doi:10.3390/toxics10040191
- 467 23. Larvie DY, Erikson KM, Armah SM. Elevated whole blood manganese is associated with
468 impaired cognition in older adults, NHANES 2013-2014 cycle. *Neurotoxicology*. Jul 2022;91:94-
469 99. doi:10.1016/j.neuro.2022.04.016
- 470 24. Wang X, Xiao P, Wang R, et al. Relationships between urinary metals concentrations and
471 cognitive performance among U.S. older people in NHANES 2011-2014. *Front Public Health*.
472 2022;10:985127. doi:10.3389/fpubh.2022.985127
- 473 25. Lu K, Liu T, Wu X, Zhong J, Ou Z, Wu W. Association between serum iron, blood lead,
474 cadmium, mercury, selenium, manganese and low cognitive performance in old adults from
475 National Health and Nutrition Examination Survey (NHANES): a cross-sectional study. *Br J*
476 *Nutr*. Nov 28 2023;130(10):1743-1753. doi:10.1017/S0007114523000740

- 477 26. Sasaki N, Carpenter DO. Associations between Metal Exposures and Cognitive Function
478 in American Older Adults. *Int J Environ Res Public Health*. Feb 17
479 2022;19(4)doi:10.3390/ijerph19042327
- 480 27. Song S, Liu N, Wang G, et al. Sex Specificity in the Mixed Effects of Blood Heavy
481 Metals and Cognitive Function on Elderly: Evidence from NHANES. *Nutrients*. Jun 25
482 2023;15(13)doi:10.3390/nu15132874
- 483 28. Kim UJ, Hong M, Choi YH. Environmental Pyrethroid Exposure and Cognitive
484 Dysfunction in U.S. Older Adults: The NHANES 2001-2002. *Int J Environ Res Public Health*.
485 Nov 16 2021;18(22)doi:10.3390/ijerph182212005
- 486 29. Yu Y, Wang Y, Dong Y, et al. Butyl benzyl phthalate as a key component of phthalate
487 ester in relation to cognitive impairment in NHANES elderly individuals and experimental mice.
488 *Environ Sci Pollut Res Int*. Apr 2023;30(16):47544-47560. doi:10.1007/s11356-023-25729-8
- 489 30. Patel CJ, Bhattacharya J, Butte AJ. An Environment-Wide Association Study (EWAS) on
490 type 2 diabetes mellitus. *PLoS One*. May 20 2010;5(5):e10746.
491 doi:10.1371/journal.pone.0010746
- 492 31. Zheng Y, Chen Z, Pearson T, Zhao J, Hu H, Prospero M. Design and methodology
493 challenges of environment-wide association studies: A systematic review. *Environ Res*. Apr
494 2020;183:109275. doi:10.1016/j.envres.2020.109275
- 495 32. Hall MA, Dudek SM, Goodloe R, et al. Environment-wide association study (EWAS) for
496 type 2 diabetes in the Marshfield Personalized Medicine Research Project Biobank. *Pac Symp*
497 *Biocomput*. 2014:200-11.
- 498 33. Patel CJ, Chen R, Kodama K, Ioannidis JP, Butte AJ. Systematic identification of
499 interaction effects between genome- and environment-wide associations in type 2 diabetes
500 mellitus. *Hum Genet*. May 2013;132(5):495-508. doi:10.1007/s00439-012-1258-z
- 501 34. Zhao J, Fan B, Huang J, et al. Environment- and epigenome-wide association study of
502 obesity in 'Children of 1997' birth cohort. *Elife*. May 19 2023;12doi:10.7554/eLife.82377
- 503 35. Uche UI, Suzuki S, Fulda KG, Zhou Z. Environment-wide association study on
504 childhood obesity in the U.S. *Environ Res*. Dec 2020;191:110109.
505 doi:10.1016/j.envres.2020.110109
- 506 36. New A, Bennett KP. A Precision Environment-Wide Association Study of Hypertension
507 via Supervised Cadre Models. *IEEE J Biomed Health Inform*. Mar 2020;24(3):916-925.
508 doi:10.1109/JBHI.2019.2918070
- 509 37. McGinnis DP, Brownstein JS, Patel CJ. Environment-Wide Association Study of Blood
510 Pressure in the National Health and Nutrition Examination Survey (1999-2012). *Sci Rep*. Jul 26
511 2016;6:30373. doi:10.1038/srep30373
- 512 38. Chi Y, Park JT, Na S, Kwak K. Environment-wide association study of elevated liver
513 enzymes: results from the Korean National Environmental Health Survey 2018-2022. *Ann Occup*
514 *Environ Med*. 2023;35:e27. doi:10.35371/aoem.2023.35.e27

- 515 39. Ni MY, Yao XI, Cheung F, et al. Determinants of physical, mental and social well-being:
516 a longitudinal environment-wide association study. *Int J Epidemiol*. Apr 1 2020;49(2):380-389.
517 doi:10.1093/ije/dyz238
- 518 40. Lopez DS, Wulaningsih W, Tsilidis KK, et al. Environment-wide association study to
519 comprehensively test and validate associations between nutrition and lifestyle factors and
520 testosterone deficiency: NHANES 1988-1994 and 1999-2004. *Hormones (Athens)*. Jun
521 2020;19(2):205-214. doi:10.1007/s42000-020-00179-w
- 522 41. Blighe K, Gurudas S, Lee Y, Sivaprasad S. Diabetic Retinopathy Environment-Wide
523 Association Study (EWAS) in NHANES 2005-2008. *J Clin Med*. Nov 12
524 2020;9(11)doi:10.3390/jcm9113643
- 525 42. Belbasis L, Bellou V, Tzoulaki I, Evangelou E. Early-Life Factors and Risk of Multiple
526 Sclerosis: An MR-EWAS. *Neuroepidemiology*. 2020;54(6):433-445. doi:10.1159/000508229
- 527 43. Zhuang X, Ni A, Liao L, et al. Environment-wide association study to identify novel
528 factors associated with peripheral arterial disease: Evidence from the National Health and
529 Nutrition Examination Survey (1999-2004). *Atherosclerosis*. Feb 2018;269:172-177.
530 doi:10.1016/j.atherosclerosis.2018.01.006
- 531 44. Zhuang X, Guo Y, Ni A, et al. Toward a panoramic perspective of the association between
532 environmental factors and cardiovascular disease: An environment-wide association study from
533 National Health and Nutrition Examination Survey 1999-2014. *Environ Int*. Sep 2018;118:146-
534 153. doi:10.1016/j.envint.2018.05.046
- 535 45. Health and nutrition examination survey plan and operations, 1999-2010. National Center
536 for Health Statistics (U.S.); 2013. <https://stacks.cdc.gov/view/cdc/21304>
- 537 46. Tulskey DS, Saklofske DH, Wilkins C, Weiss LG. Development of a general ability index
538 for the Wechsler Adult Intelligence Scale--Third Edition. *Psychol Assess*. Dec 2001;13(4):566-71.
539 doi:10.1037//1040-3590.13.4.566
- 540 47. Donohue MC, Sperling RA, Salmon DP, et al. The preclinical Alzheimer cognitive
541 composite: measuring amyloid-related decline. *JAMA Neurol*. Aug 2014;71(8):961-70.
542 doi:10.1001/jamaneurol.2014.803
- 543 48. Amieva H, Meillon C, Proust-Lima C, Dartigues JF. Is Low Psychomotor Speed a
544 Marker of Brain Vulnerability in Late Life? Digit Symbol Substitution Test in the Prediction of
545 Alzheimer, Parkinson, Stroke, Disability, and Depression. *Dement Geriatr Cogn Disord*.
546 2019;47(4-6):297-305. doi:10.1159/000500597
- 547 49. Jaeger J. Digit Symbol Substitution Test: The Case for Sensitivity Over Specificity in
548 Neuropsychological Testing. *J Clin Psychopharmacol*. Oct 2018;38(5):513-519.
549 doi:10.1097/JCP.0000000000000941
- 550 50. Promotion NcfCDPaH. *National Health Statistics Reports: Cognitive Performance in*
551 *Adults Aged 60 and Over: National Health and Nutrition Examination Survey, 2011–2014*. 2019.
552 September 17, 2019. chrome-
553 extension://efaidnbmninnibpcajpcgclclefindmkaj/[https://www.cdc.gov/nchs/data/nhsr/nhsr126-](https://www.cdc.gov/nchs/data/nhsr/nhsr126-508.pdf)
554 [508.pdf](https://www.cdc.gov/nchs/data/nhsr/nhsr126-508.pdf)

- 555 51. Li S, Sun W, Zhang D. Association of Zinc, Iron, Copper, and Selenium Intakes with Low
556 Cognitive Performance in Older Adults: A Cross-Sectional Study from National Health and
557 Nutrition Examination Survey (NHANES). *J Alzheimers Dis.* 2019;72(4):1145-1157.
558 doi:10.3233/jad-190263
- 559 52. Chen SP, Bhattacharya J, Pershing S. Association of Vision Loss With Cognition in Older
560 Adults. *JAMA Ophthalmol.* Sep 1 2017;135(9):963-970. doi:10.1001/jamaophthalmol.2017.2838
- 561 53. CDC/National Center for Health Statistics. NHANES 1999-2000 Laboratory Methods.
562 <https://wwwn.cdc.gov/nchs/nhanes/continuousnhanes/labmethods.aspx?Cycle=1999-2000>
- 563 54. CDC/National Center for Health Statistics. NHANES 2001-2002 Laboratory Methods.
564 <https://wwwn.cdc.gov/nchs/nhanes/continuousnhanes/labmethods.aspx?BeginYear=2001>
- 565 55. Centers for Disease Control and Prevention. *National Health Nutrition Examination*
566 *Survey (NHANES) Laboratory Procedures Manual.* 2011.
567 <https://wwwn.cdc.gov/nchs/nhanes/continuousnhanes/manuals.aspx?BeginYear=2011>
- 568 56. Centers for Disease Control and Prevention. *National Health Nutrition Examination*
569 *Survey (NHANES) Laboratory Procedures Manual.* 2013.
570 <https://wwwn.cdc.gov/nchs/nhanes/continuousnhanes/manuals.aspx?BeginYear=2013>
- 571 57. Nguyen VK, Middleton LYM, Huang L, et al. Harmonized US National Health and
572 Nutrition Examination Survey 1988-2018 for high throughput exposome-health discovery.
573 *medRxiv.* Feb 8 2023;doi:10.1101/2023.02.06.23284573
- 574 58. Hales CM, Carroll MD, Fryar CD, Ogden CL. *Prevalence of obesity and severe obesity*
575 *among adults: United States, 2017–2018.* NCHS Data Brief, no 360. Hyattsville, MD: National
576 Center for Health Statistics; 2020.
- 577 59. Kim S. Overview of Cotinine Cutoff Values for Smoking Status Classification. *Int J*
578 *Environ Res Public Health.* Dec 14 2016;13(12)doi:10.3390/ijerph13121236
- 579 60. National Center for Health Statistics, Centers for Disease Control and Prevention.
580 *Analytic and reporting guidelines: The National Health and Nutrition Examination Survey*
581 *(NHANES) 2006.*
- 582 61. Chung MK, Buck Louis GM, Kannan K, Patel CJ. Exposome-wide association study of
583 semen quality: Systematic discovery of endocrine disrupting chemical biomarkers in fertility
584 require large sample sizes. *Environ Int.* Apr 2019;125:505-514. doi:10.1016/j.envint.2018.11.037
- 585 62. Chen P, Miah MR, Aschner M. Metals and Neurodegeneration. *F1000Res.*
586 2016;5doi:10.12688/f1000research.7431.1
- 587 63. Olasehinde TA, Olaniran AO. Neurotoxicity of Polycyclic Aromatic Hydrocarbons: A
588 Systematic Mapping and Review of Neuropathological Mechanisms. *Toxics.* Jul 25
589 2022;10(8)doi:10.3390/toxics10080417
- 590 64. Pessah IN, Lein PJ, Seegal RF, Sagiv SK. Neurotoxicity of polychlorinated biphenyls and
591 related organohalogens. *Acta Neuropathol.* Sep 2019;138(3):363-387. doi:10.1007/s00401-019-
592 01978-1

- 593 65. Zhao Y, Chang YH, Ren HR, et al. Phthalates Induce Neurotoxicity by Disrupting the
594 Mfn2-PERK Axis-Mediated Endoplasmic Reticulum-Mitochondria Interaction. *J Agric Food*
595 *Chem.* Apr 3 2024;72(13):7411-7422. doi:10.1021/acs.jafc.3c07752
- 596 66. Richardson JR, Fitsanakis V, Westerink RHS, Kanthasamy AG. Neurotoxicity of
597 pesticides. *Acta Neuropathol.* Sep 2019;138(3):343-362. doi:10.1007/s00401-019-02033-9
- 598 67. Ali H, Khan E, Ilahi I. Environmental Chemistry and Ecotoxicology of Hazardous Heavy
599 Metals: Environmental Persistence, Toxicity, and Bioaccumulation. *J Chem-Ny.*
600 2019;2019doi:Artn 6730305
601 10.1155/2019/6730305
- 602 68. Casale J, AS R. Phthalates Toxicity. *StatPearls.* 2023.
- 603 69. Sun K, Song Y, He F, Jing M, Tang J, Liu R. A review of human and animals exposure to
604 polycyclic aromatic hydrocarbons: Health risk and adverse effects, photo-induced toxicity and
605 regulating effect of microplastics. *Sci Total Environ.* Jun 15 2021;773:145403.
606 doi:10.1016/j.scitotenv.2021.145403
- 607 70. Crinnion WJ. Polychlorinated biphenyls: persistent pollutants with immunological,
608 neurological, and endocrinological consequences. *Altern Med Rev.* Mar 2011;16(1):5-13.
- 609 71. Wei Y, Zhou J, Zhao F, et al. Association of blood lead exposure with frailty and its
610 components among the Chinese oldest old. *Ecotoxicol Environ Saf.* Sep 1 2022;242:113959.
611 doi:10.1016/j.ecoenv.2022.113959
- 612 72. Gundacker C, Forsthuber M, Szigeti T, et al. Lead (Pb) and neurodevelopment: A review
613 on exposure and biomarkers of effect (BDNF, HDL) and susceptibility. *Int J Hyg Environ Health.*
614 Sep 2021;238:113855. doi:10.1016/j.ijheh.2021.113855
- 615 73. Vig EK, Hu H. Lead toxicity in older adults. *J Am Geriatr Soc.* Nov 2000;48(11):1501-6.
- 616 74. Lv Y, Wei Y, Zhou J, et al. Human biomonitoring of toxic and essential metals in younger
617 elderly, octogenarians, nonagenarians and centenarians: Analysis of the Healthy Ageing and
618 Biomarkers Cohort Study (HABCS) in China. *Environ Int.* Nov 2021;156:106717.
619 doi:10.1016/j.envint.2021.106717
- 620 75. Lasley SM, Gilbert ME. Glutamatergic components underlying lead-induced impairments
621 in hippocampal synaptic plasticity. *Neurotoxicology.* Dec 2000;21(6):1057-68.
- 622 76. Ahamed M, Siddiqui MK. Low level lead exposure and oxidative stress: current opinions.
623 *Clin Chim Acta.* Aug 2007;383(1-2):57-64. doi:10.1016/j.cca.2007.04.024
- 624 77. Adonaylo VN, Oteiza PI. Pb²⁺ promotes lipid oxidation and alterations in membrane
625 physical properties. *Toxicology.* Jan 1 1999;132(1):19-32. doi:10.1016/s0300-483x(98)00134-6
- 626 78. Navas-Acien A, Guallar E, Silbergeld EK, Rothenberg SJ. Lead exposure and
627 cardiovascular disease--a systematic review. *Environ Health Perspect.* Mar 2007;115(3):472-82.
628 doi:10.1289/ehp.9785

- 629 79. Hu H, Rabinowitz M, Smith D. Bone lead as a biological marker in epidemiologic studies
630 of chronic toxicity: conceptual paradigms. *Environ Health Perspect.* Jan 1998;106(1):1-8.
631 doi:10.1289/ehp.981061
- 632 80. Ge S, Ma W, Qu Z, et al. Urinary tobacco-specific nitrosamine 4-(methylnitrosamino)-1-
633 (3-pyridyl)-1-butanol (NNAL) and cognitive functioning in older adults: The National Health
634 and Nutrition Examination Survey 2013-2014. *Tob Induc Dis.* 2023;21:68.
635 doi:10.18332/tid/162368
- 636 81. Yalcin E, de la Monte S. Tobacco nitrosamines as culprits in disease: mechanisms
637 reviewed. *J Physiol Biochem.* Mar 2016;72(1):107-20. doi:10.1007/s13105-016-0465-9
- 638 82. Bovet L, Campanoni P, Lu J, et al. CLCNt2 Mediates Nitrate Content in Tobacco Leaf,
639 Impacting the Production of Tobacco-Specific Nitrosamines in Cured Leaves. *Front Plant Sci.*
640 2022;13:741078. doi:10.3389/fpls.2022.741078
- 641 83. Boo HJ, Min HY, Hwang SJ, et al. The tobacco-specific carcinogen NNK induces
642 pulmonary tumorigenesis via nAChR/Src/STAT3-mediated activation of the renin-angiotensin
643 system and IGF-1R signaling. *Exp Mol Med.* Jun 2023;55(6):1131-1144. doi:10.1038/s12276-
644 023-00994-2
- 645 84. Dubey D, Sharma VD, Pass SE, Sawhney A, Stuve O. Para-dichlorobenzene toxicity - a
646 review of potential neurotoxic manifestations. *Ther Adv Neurol Disord.* May 2014;7(3):177-87.
647 doi:10.1177/1756285614521889
- 648 85. Budny JA. Encyclopedia of Toxicology, 3rd edition. *Int J Toxicol.* Jul-Aug
649 2015;34(4):366-367. doi:10.1177/1091581815586498
- 650 86. Suhua W, Rongzhu L, Changqing Y, et al. Lipid peroxidation and changes of trace
651 elements in mice treated with paradichlorobenzene. *Biol Trace Elem Res.* Sep 2010;136(3):320-
652 36. doi:10.1007/s12011-009-8552-1
- 653 87. Oikawa S, Kawanishi S. Copper-mediated DNA damage by metabolites of p-
654 dichlorobenzene. *Carcinogenesis.* Dec 1996;17(12):2733-9. doi:10.1093/carcin/17.12.2733
- 655 88. Feigin VL, Forouzanfar MH, Krishnamurthi R, et al. Global and regional burden of
656 stroke during 1990-2010: findings from the Global Burden of Disease Study 2010. *Lancet.* Jan
657 18 2014;383(9913):245-54. doi:10.1016/s0140-6736(13)61953-4
- 658 89. Valko M, Morris H, Cronin MT. Metals, toxicity and oxidative stress. *Curr Med Chem.*
659 2005;12(10):1161-208. doi:10.2174/0929867053764635
- 660 90. Al-Qazzaz NK, Ali SH, Ahmad SA, Islam S, Mohamad K. Cognitive impairment and
661 memory dysfunction after a stroke diagnosis: a post-stroke memory assessment. *Neuropsychiatr*
662 *Dis Treat.* 2014;10:1677-91. doi:10.2147/NDT.S67184
- 663 91. Cullen B, O'Neill B, Evans JJ, Coen RF, Lawlor BA. A review of screening tests for
664 cognitive impairment. *J Neurol Neurosurg Psychiatry.* Aug 2007;78(8):790-9.
665 doi:10.1136/jnnp.2006.095414

666 92. Carreras G, Miccinesi G, Wilcock A, et al. Missing not at random in end of life care
667 studies: multiple imputation and sensitivity analysis on data from the ACTION study. *BMC Med*
668 *Res Methodol.* Jan 9 2021;21(1):13. doi:10.1186/s12874-020-01180-y

669